Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 292

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance

Open access
McMahon, Moira A., Jilek, Benjamin L., Brennan, Timothy P., Shen, Lin, Zhou, Yan, Wind-Rotolo, Megan, Xing, Sifei, Bhat, Shridhar, Hale, Braden, Hegarty, Robert, Chong, Curtis R., Liu, Jun O., Siliciano, Robert F., Thio, Chloe L.·2007·New England Journal of Medicine

Abstract

Sum m a r yEntecavir, a drug approved by the Food and Drug Administration for the treatment of chronic hepatitis B virus (HBV) infection, is not believed to inhibit replication of human immunodeficiency virus type 1 (HIV-1) at clinically relevant doses.We observed that entecavir led to a consistent 1-log 10 decrease in HIV-1 RNA in three persons with HIV-1 and HBV coinfection, and we obtained supportive in vitro evidence that entecavir is a potent partial inhibitor of HIV-1 replication.Detailed analysis showed that in one of these patients, entecavir monotherapy led to an accumulation of HIV-1 variants with the lamivudine-resistant mutation, M184V.In vitro experiments showed that M184V confers resistance to entecavir.Until more is known about HIV-1-resistance patterns and their selection by entecavir, caution is needed with the use of entecavir in persons with HIV-1 and HBV coinfection who are not receiving fully suppressive antiretroviral regimens. Entecavir, an analogue of 2′-deoxyguanosine, is converted intracellularly to an active 5′-triphosphate form that inhibits hepatitis B virus (HBV) polymerase.[1][2][3] Entecavir is approved by the Food and Drug Administration for the treatment of chronic hepatitis B infection.A previous study 1 indicated that it has no clinically relevant activity against human immunodeficiency virus type 1 (HIV-1), and the package insert states that the concentration needed to inhibit replication by 50% (EC 50 ) for HIV-1 is greater than 1 μM, which is higher than concentrations achieved in vivo with dosages used to treat chronic hepatitis B. Because of this selective activity against HBV, 4-7 several treatment guidelines, including the U.S. Public Health Service guidelines, recommend entecavir for hepatitis B treatment in HIV-1-infected persons who do not meet criteria for HIV-1 treatment.[8][9][10][11] Here, we report that entecavir has clinically relevant activity against HIV-1 and can select HIV-1 variants resistant to the widely used antiretroviral drugs lamivudine and emtricitabine. C a se R ep or t s Patient 1Patient 1 is a 31-year-old white man with HIV-1 and HBV coinfection who tested seropositive for HIV-1 in 1990.In 2000, he received zidovudine, lamivudine, and nevirapine for the treatment of HIV-1.He took these drugs intermittently for less than 1 year.In February 2002, his CD4+ T-cell count was 596 cells per cubic millimeter,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa067710

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 292

Metadata

Authors
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., Chong, C. R., Liu, J. O., Siliciano, R. F., & Thio, C. L.
Venue
New England Journal of Medicine
Published
2007-06-21
Volume
356
Issue
25
Pages
2614-2621
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1981526509
Cited by
292
References
21
FWCI
27.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance. https://app.cochat.ai/papers/10.1056/nejmoa067710
The paper
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., Chong, C. R., Liu, J. O., Siliciano, R. F., & Thio, C. L. (2007). The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance. New England Journal of Medicine. https://doi.org/10.1056/nejmoa067710

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.